Respiratory Syncytial Virus

Pharmacists are essential in preventing the significant health and economic burden of respiratory syncytial virus (RSV) infections in older adults through vaccination.

Rates of GBS were similar between Arexvy and Abrysvo, at 0.12% and 0.11% of total reported events, respectively.

Reduced hospital masking and testing policies increased rates of hospital-onset respiratory infections, including RSV.

Researchers developed a method to stabilize respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) fusion (F) proteins, advancing potential vaccines for both viruses.

Findings highlight the unmet medical need for outpatient interventions and preventive measures that can reduce hospitalizations.

Use of in-room air purifiers with HEPA-14 filters did not result in a significant reduction of acute respiratory infections.

Increasing vaccine coverage among adults at highest risk could lessen associated hospitalizations and severe outcomes caused by RSV.

RSV vaccination is approximately 77% to 81% effective against hospital and emergency department encounters among older adults.

RSV vaccines were 80% effective in preventing hospitalization, ICU admission, and death among adults aged 60 years and older.

Findings suggest further need to educate the public on receiving an indicated vaccine as we approach peak respiratory syncytial virus (RSV) season.

The approval marks Abrysvo as the first and only RSV vaccine designated for adults younger than 50 that are at increased risk for LRTD.

New ACIP recommendations provide clarity, but questions linger for those aged 60 to 74 years.

The connection of F proteins could help destabilize the virus prior to infection of the next host.

A single dose RSV vaccine per year can offer optimal protection against 3 full RSV seasons.

RSV vaccination could be cost-effective among adults 60 years and older, with the ability to decrease vaccine costs and sustain efficacy.

Adults with underlying medical conditions, resulting in an increased risk of respiratory syncytial virus disease are more likely to be cost-effective than general age-based strategies.

Results displayed a non-inferior immune response of the co-administered vaccines, compared to administration in individual visits.

Programs can take several forms, including on-site clinics, voucher programs, and in-store events

RSV vaccination was 75% effective in preventing RSV-associated hospitalizations among adults aged 60 years and older.

Shared clinical decision-making presented drawbacks, resulting in age-based recommendations for adults aged 75 years and older and risk-based recommendations for individuals aged 60-74 years.

The findings further the understanding of respiratory virus immune evasion mechanisms and uncover how RSV-NS1 can target therapeutic intervention

Individuals with chronic conditions like asthma, diabetes, and chronic obstructive pulmonary disease face an increased risk of developing RSV.

The mRNA-1345 vaccine provides a one-off mechanism of protection because of its single-dose prefilled syringes

Educate patients about the importance of vaccination in preventing severe disease.

Providing immunization coadministration and assisting with insurance coverage are strategies to improve access.

Understanding preventive care reduces the risk of illnesses and decreases future costs.

Differentiating between the 3 available options can help identify which is best for individual patients.

Pharmacists’ awareness of respiratory syncytial virus and their role in educating about the vaccine have grown dramatically.

The ACIP recommendations are designed to improve access to RSV vaccination, emphasizing the need to get vaccinated.

Carrie Koenigsfeld, PharmD, FAPhA, explores the potential contraindications that may preclude individuals from receiving an RSV vaccine.